

Stent Oesophageal Varices: Effective haemostasis using self-expandable covered mesh-metal oesophageal stents versus standard endoscopic therapy in the emergency treatment of oesophageal variceal haemorrhage

Submission date 03/05/2013	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 03/05/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 25/04/2019	Condition category Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Twice as many people now die from liver disease than in 1991, making liver disease the fifth big killer in England & Wales, with most deaths occurring in those under 60. Bleeding from veins in the gullet (Oesophageal varices) is one of the most serious complications of liver disease carrying a 1-in-5 risk of a patient dying. Current best treatments involve using medications to reduce bleeding and passing a camera, on the end of a narrow flexible tube called an endoscope, into the gullet to find the source of bleeding and stop it. Unfortunately the chances of this treatment failing to control the bleeding are about 1-in-4.

We are testing a device called a stent. This is a covered mesh-metal tube which is placed in the gullet using the endoscope. The stent expands to push on the walls of the gullet and stop the veins from bleeding.

Who can participate?

All patients who are admitted to participating hospitals with bleeding from veins in the gullet will be offered the opportunity to participate.

What does the study involve?

Participants will be randomly allocated to one of the two groups:

1. Oesophageal Stent
2. The best current treatments

This study will compare the new stent with the best current treatments

What are the possible benefits and risks of participating?

The stent has been used in a small number of patients and is currently reported to be 100%

successful at stopping bleeding. There are some minor complications, which can occur with the stent such as inflammation of the gullet, acid reflux from the stomach and very rarely perforation of the gullet. These will be discussed in full with all potential participants.

Where is the study run from?

The Co-ordinating centre is the Royal Free Hospital (UK)

There are 10 UK centres in total:

The Royal Free Hospital, London (Lead centre)

Bristol Royal Infirmary

The Royal London Hospital

Frimley Park Hospital, Surrey

Basildon & Thurrock University Hospitals

Royal Devon & Exeter Hospitals

Central Manchester University Hospitals

Royal Bournemouth Hospital, Dorset

Queen Alexandra Hospital, Portsmouth

University Hospitals Coventry & Warwickshire

When is the study starting and how long is it expected to run for?

The study is open now and will run until 2015.

Who is funding the study?

The study is being supported by a grant from ELLA CS (the company that make the stents), and by the National Institute of Health Research.

Who is the main contact?

Dr Brian Hogan

brianhogan@nhs.net

Contact information

Type(s)

Scientific

Contact name

Dr Brian Hogan

Contact details

Royal Free Hospital

Pond Street

London

United Kingdom

NW3 2QG

+44 20 7794 0500

brianhogan@nhs.net

Additional identifiers

ClinicalTrials.gov (NCT)

NCT01851564

Protocol serial number

13392

Study information

Scientific Title

Effective haemostasis using self-expandable covered mesh-metal oesophageal stents versus standard endoscopic therapy in the emergency treatment of oesophageal variceal haemorrhage: A multicentre, open, prospective, randomised, controlled study

Acronym

SOV

Study objectives

The self-expanding oesophageal stent will:

1. Provide superior haemostasis and a reduction in failure to control bleeding when compared to standard endoscopic therapy
2. Be successfully implanted and well tolerated in >95% of the selected participants
3. Be associated with fewer minor side-effects for the participant (thoracic pain, dysphagia), and with earlier introduction of oral feeding when compared to standard endoscopic therapy

Ethics approval required

Old ethics approval format

Ethics approval(s)

11/LO/1873

Study design

Multicentre open prospective randomised controlled treatment study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Blood, Oral and Gastrointestinal; Subtopic: Blood (all Subtopics), Oral and Gastrointestinal (all Subtopics); Disease: Non-malignant haematology, Hepatology

Interventions

Oesophageal Stent compared with the best current treatments

Oesophageal Stent, A self-expanding mesh metal removable oesophageal stent.

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

Failure to control bleeding (as defined by the Baveno V criteria) or re-bleeding within 7 days.

Key secondary outcome(s)

Not provided at time of registration

Completion date

31/08/2014

Eligibility

Key inclusion criteria

Arm 1:

Participants with Child-Pugh grade B or C cirrhosis with variceal haemorrhage, where the bleeding is from a site which would ordinarily be treated with band ligation (usually either oesophageal or GOV-1 varices). The diagnosis of cirrhosis may be proven by previous histology or suspected using clinical, radiological and biochemical data.

Arm 2: Participants with Child-Pugh grade A, B or C cirrhosis who present with failure to control bleeding within 5 days of an initial attempt at standard endoscopic therapy of acute haemorrhage from a site which would ordinarily be treated with band ligation (usually either oesophageal or GOV-1 varices).

Failure to control bleeding is demonstrated by the Baveno V criteria, either:

1. Fresh Haematemesis (or >100mls of fresh blood aspirated via NG >2 hours after therapeutic endoscopy)
2. Development of Hypovolaemic Shock
3. 3g drop in Haemoglobin within any 24 hours period if no transfusion is administered

Target Gender: Male & Female ; Lower Age Limit 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. < 18 Years of age
2. Child-Pugh grade A cirrhosis (Arm 1 only)
3. Non-cirrhotic portal hypertension

4. Malignancy of the oesophagus, stomach or upper respiratory tract
5. Oesophageal stenosis which prohibits endoscopy
6. Recent oesophageal surgery
7. A large hiatus hernia which prevents stent placement
8. Known hepatocellular carcinoma considered to be incurable (according to Milan Criteria).
9. Patients in the terminal phases of hepatological or other disease.
10. Pregnancy

Date of first enrolment

22/08/2012

Date of final enrolment

31/08/2014

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Royal Free Hospital

London

United Kingdom

NW3 2QG

Sponsor information

Organisation

University College London (UK)

ROR

<https://ror.org/02jx3x895>

Funder(s)

Funder type

Industry

Funder Name

ELLA - CS, s.r.o.

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes